About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.
Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about the therapeutic and other potential of
niacin receptor agonists; the results of the Phase 1 clinical trial of a
second generation niacin receptor agonist; the continuation and progress of
the collaboration between Merck and Arena and the activities and program
thereunder; the niacin receptor's potential in regulating plasma lipid
profiles; the potential of drugs that influence HDL cholesterol to provide
clinical benefits to patients; and about Arena's strategy, internal and
partnered programs, and ability to develop compounds and commercialize
drugs. For such statements, Arena claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results may
differ materially from Arena's expectations. Factors that could cause
actual results to differ
|SOURCE Arena Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved